Pharmacologic Therapy for Heart Failure with Reduced Ejection Fraction: Closing the Gap Between Clinical Guidelines and Practice

Despite the great progress made in the management of heart failure (HF) with reduced ejection fraction (HFrEF), its prevalence continues to rise owing to an aging population and an epidemic of hypertension, obesity and coronary artery disease. For decades, angiotensin converting enzyme inhibitors and beta blockers have been the mainstay of HFrEF therapy. The recent addition of sacubitril/valsartan and ivabradine to the HF armamentarium has the potential to transform our therapeutic approach to HFrEF, while simultaneously raising some questions and uncertainties on their applicability.

Source: Progress in Cardiovascular Diseases - August 25, 2017 Category: Cardiology Authors: J. Barr Biglane, Miriam F. Becnel, Hector O. Ventura, Selim R. Krim Source Type: research